Latest Breaking News On - ஜான்சன் நடுத்தர - Page 2 : comparemela.com

Janssen’s Erleada maintains quality of life for prostate cancer patients 27th May 2021 Janssen’s Erleada in addition to androgen deprivation therapy (ADT) maintained prostate cancer patients’ health-related quality of life (HRQoL), according to new patient-reported outcomes (PRO) data. The PRO data from the prespecified final analysis of the Phase III TITAN study in patients with metastatic hormone-sensitive prostate cancer (mHSPC) also showed that the addition of Erleada (apalutamide) to ADT did not worse side effect burden. In both treatment groups – patients who received Erleada plus ADT and patients who received placebo plus ADT – HRQoL was maintained throughout the study.

Janssen erleadaCatherine taylorBrief pain inventory short formFunctional assessmentCancer therapy prostateMiddle eastJohnson middleProstate cancerகேத்தரின் டெய்லர்சுருக்கமான வலி சரக்கு குறுகிய வடிவம்செயல்பாட்டு மதிப்பீடுபுற்றுநோய் சிகிச்சை ப்ராஸ்டேட்நடுத்தர கிழக்குஜான்சன் நடுத்தர